Mettler Toledo (MTD)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$1248.96-3.60%
Close 2026-07-08 · 1-day change
Reading MTD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MTD free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading MTD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MTD free→QuarterlyIQ Insights · MTD
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. Current price $1248.96. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $1,296 MTD trades at 31× p/e, below its 35× p/e peer median, but our blended $1,195 fair value sits below the price. It's a high-confidence read. Analysts target $1,194–$1,500. Not investment advice.
$1194.00 – $1500.00 (median $1375.00) · 4 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 73% over what the business is worth with no growth; closing that gap needs roughly 40.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $42.29/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $1375.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $557.01 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $487.32 | — | — | Hist. CAGR | high |
| Mgmt guidance | 12M | $1601.88 | 34.4 | 46.63 | Mgmt | high |
| Peer P/FCF | 12M | $1195.21 | 30.6 | 39.03 | TTM | high |
| Peer P/E | 12M | $1502.11 | 34.4 | 43.72 | TTM | high |
| Peer P/S | 12M | $712.99 | 3.5 | 201.09 | TTM | high |
| PEG | 12M | $2197.02 | 50.3 | 43.72 | TTM | high |
| Own P/E history | 12M | $1336.86 | 30.6 | 43.72 | TTM | high |
| triangulated | 12M | $1527.47 | 34.4 | 44.46 | Triangulated | high |
| Mgmt guidance | 3Y | $2359.04 | 34.4 | 68.66 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $1191.65 | 30.6 | 38.92 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $1919.78 | 34.4 | 55.88 | Analyst | medium |
| Peer P/S | 3Y | $842.11 | 3.5 | 237.50 | Analyst | medium |
| PEG | 3Y | $2807.93 | 50.3 | 55.88 | Analyst | medium |
| Own P/E history | 3Y | $1708.58 | 30.6 | 55.88 | Analyst | medium |
| Mgmt guidance | 5Y | $3053.55 | 34.4 | 88.88 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $1189.28 | 30.6 | 38.84 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $2139.98 | 34.4 | 62.29 | Analyst | high |
| Peer P/S | 5Y | $938.69 | 3.5 | 264.74 | Analyst | high |
| PEG | 5Y | $3129.99 | 50.3 | 62.29 | Analyst | high |
| Own P/E history | 5Y | $1904.56 | 30.6 | 62.29 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.